PropThink: Lower Dificid Price Doesn’t Resonate With Analysts; OPTR Could Trade Lower

[ACN Newswire] – By David MoskowitzYesterday, Optimer Pharmaceuticals (NASDAQ:OPTR) hosted its Analyst Day, describing a new lower pricing policy with hospitals to spur demand of Dificid. Our negative view of the meeting … more

View todays social media effects on CBST

View the latest stocks trending across Twitter. Click to view dashboard